Mark G Alexandrow (Mark Alexandrow)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Venues

Oncogene

Molecular cancer therapeutics

Research square

Cancer

H Lee Moffitt Cancer Center and Research Institute

Vanderbilt University Medical Center (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

H Lee Moffitt Cancer Center and Research Institute Sep 20 2005

United States

Associate Professor/Member :: Molecular Oncology

University of Virginia Medical Center Jan 01 1997 - Aug 31 2005

United States

Postdoctoral Fellow :: Biochemistry and Molecular Genetics

Education History

Vanderbilt University Medical Center Aug 31 1991 - Mar 15 1996

United States

PHD :: Cell Biology

Publications

Shengyan Xiang, Kendall C Craig, Xingju Luo, Darcy L Welch, Renan B Ferreira, Harshani R Lawrence, Nicholas J Lawrence, Damon R Reed, Mark G Alexandrow
Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function. Molecular cancer therapeutics (2024)
Shengyan Xiang, Kendall C Craig, Xingju Luo, Darcy L Welch, Renan B Ferreira, Harshani R Lawrence, Nicholas J Lawrence, Damon R Reed, Mark G Alexandrow
Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function. Molecular cancer therapeutics (2024)
Shengyan Xiang, Kendall C Craig, Xingju Luo, Darcy L Welch, Renan B Ferreira, Harshani R Lawrence, Nicholas J Lawrence, Damon R Reed, Mark G Alexandrow
Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function. Molecular cancer therapeutics (2024)
Mark G Alexandrow, Shengyan Xiang, Xingju Luo, Darcy Welch, Damon Reed
Identification of Selective ATP-Competitive CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function. Research square (2023)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Shengyan Xiang, Damon R Reed, Mark G Alexandrow
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene 42 (7) (2022)
Damon R Reed, Jonathan Metts, Mariyah Pressley, Brooke L Fridley, Masanori Hayashi, Michael S Isakoff, David M Loeb, Rikesh Makanji, Ryan D Roberts, Matteo Trucco, Lars M Wagner, Mark G Alexandrow, Robert A Gatenby, Joel S Brown
An evolutionary framework for treating pediatric sarcomas. Cancer 126 (11) (2020)

Mark G Alexandrow.css-eqlu8i{font-size:small;padding-left:4px;} (Mark Alexandrow)

Publication Activity (10 Years)

Top Topics

Top Venues

Mark G Alexandrow (Mark Alexandrow)